All PlansCoverageLow impact
KIF6 Genotyping for Predicting Cardiovascular Risk and/or Effectiveness of Statin Therapy
Blue Cross & Blue Shield of Mississippi·Cardiology, Internal Medicine, Family Medicine·Medical Policy
Effective date
Aug 1, 2025
We identified it
Jun 20, 2026
Summary
KIF6 genotyping for cardiovascular risk prediction and statin therapy effectiveness remains classified as investigational and not covered. This policy was reviewed with no changes as of August 1, 2025.
Action Required
No immediate action required. Billing team should continue to deny or not submit claims for KIF6 genotyping tests using CPT codes 81479 or 84999, as these remain investigational and non-covered services. If providers order these tests, inform them of non-coverage status.